Last updated on March 2020

Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease

Brief description of study

The primary objective of the study is to evaluate the efficacy of AGB101 on slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with mild cognitive impairment due to Alzheimer's Disease (MCI due to AD) also known as prodromal AD. Participants will be randomized to receive placebo or AGB101 (220 mg), once daily for 78 weeks. Secondary objectives are to assess the effect of AGB101 compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE) and Functional Activities Questionnaire (FAQ).

Clinical Study Identifier: NCT03486938

Find a site near you

Start Over

The Roskamp Institute, Inc

Sarasota, FL United States
  Connect »